Healthy
subjects who received increasing doses of albiglutide showed
a trend of dose-dependent reduction in glucose and fructosamine
levels. In these healthy subjects, there were no dosedependent
effects seen for glucagon, insulin, or C-peptide
concentrations.12 In a study of Japanese patients with type
2 diabetes mellitus who were randomized to receive albiglutide
15 mg or 30 mg once weekly, 50 mg every 2 weeks, or
100 mg monthly, the mean weighted glucose (area under the
curve) after 4 weeks was significantly decreased in all patients
except for those who received the 100 mg dose (all P0.002
except for the 100 mg dose, P=0.065).